Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01618955 · ClinicalTrials.gov registry record · Phase 2
Actual Human Use of Methotrexate (MTX) Subcutaneously Administered Via the VIBEX™ MTX Auto-Injector Device
A Phase 2 study, sponsored by Antares Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 101
- Enrollment target
NCT01618955 is a Phase 2 study that has completed, run by Antares Pharma. The registered enrollment target is 101 participants.
The verdict
NCT01618955, a Phase 2 study, has completed, sponsored by Antares Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 101 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the usability of the VIBEX MTX device for SC self-injection of methotrexate.
Interventions
- DEVICE VIBEX MTX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2012-05 |
| Est. Completion | 2012-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01618955
The ClinicalTrials.gov registry entry for NCT01618955 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Antares Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VIBEX MTX is the first listed.
NCT01618955 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01618955 about?
NCT01618955 is a clinical study titled "Actual Human Use of Methotrexate (MTX) Subcutaneously Administered Via the VIBEX™ MTX Auto-Injector Device". The purpose of this study is to assess the usability of the VIBEX MTX device for SC self-injection of methotrexate.
What is the current status of trial NCT01618955?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2012-05. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01618955?
The interventions under investigation include: VIBEX MTX (DEVICE).
Who is sponsoring clinical trial NCT01618955?
This trial is sponsored by Antares Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.